HLH across speciality collaboration, UK
Consider tirzepatide (Zepbound/Mounjaro) if: You want a proven, FDA-approved medication available today You prefer a drug with years of real-world safety data You have insurance coverage for weight management medications You have type 2 diabetes (Mounjaro is indicated for T2D) You are sensitive to GI side effects (lower nausea rate: 31% vs 43%) You want the option of pre-filled pens for easier injection Consider waiting for retatrutide if: You have plateaued on tirzepatide or semaglutide and want the next-generation option You have MASLD or fatty liver disease (glucagon component reduces liver fat by 82%) Maximum possible weight loss is your primary goal You are eligible for and enrolled in a clinical trial You are comfortable waiting until 2027-2028 for availability On switching from tirzepatide to retatrutide: Once retatrutide is approved, switching will likely be straightforward since both are Lilly products
Le Noun C, Nelson CE, Liu X, Park HS, Matsuoka Y, Luongo C, et al
As with any wellness change, results vary from person to person
For intradermal injection, substances must be solubilized in sterile water, and mixtures should be avoided, with different substances injected via separate syringes
Start by reviewing your plan policy, which you may have received a copy of in the mail